← Full evidence page

For the cleanest result, disable browser headers and footers.

Dediabetes Evidence Brief

Liraglutide for Diabetes: Evidence and Outcomes

Evidence related to liraglutide and liraglutide-containing intervention regimens in diabetes studies.

Brief accessed
—

Full evidence pagehttps://www.dediabetes.com/evidence/liraglutide

Executive Summary

Liraglutide evidence appears to center on HbA1c.

Among 25 indexed studies and 3 interventions, the strongest signals are summarized from the available evidence. Body weight has been studied often, while HbA1c appears to have stronger current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Evidence Snapshot

Studies analyzed
25
Evidence relationships
89
Interventions
3
Outcomes
86
Strong evidence signals
4
Mixed evidence areas
2

Key Findings

  1. 01

    Across 7 studies, Liraglutide shows a consistent moderate positive signal for HbA1c.

  2. 02

    Across 7 studies, Liraglutide shows a consistent moderate positive signal for Body weight.

  3. 03

    Across 3 studies, Liraglutide shows a consistent strong positive signal for Systolic blood pressure.

  4. 04

    Across 3 studies, Liraglutide shows a consistent moderate positive signal for BMI.

Question Highlights

What outcomes has Liraglutide been studied for?

HbA1c, Body weight, and Systolic blood pressure are among the most studied areas in relation to Liraglutide.

HbA1c, Body weight, and Systolic blood pressure are among the best-supported options in the available evidence across 25 studies.

Read the full answer

Does Liraglutide lower HbA1c?

Liraglutide may lower HbA1c.

Strong evidence is based on 7 supporting studies.

Read the full answer

How does Liraglutide compare across studied outcomes?

HbA1c, Body weight, and Systolic blood pressure have available evidence for Liraglutide, but the comparison requires review of the underlying studies.

Evidence is available for both Body weight and HbA1c; the underlying studies are needed for a direct comparison.

Read the full answer

Evidence Categories

The evidence is organized by how consistently it supports a conclusion and how much research is available.

Well-Supported Interventions

The strongest and most consistent evidence for improving this outcome.

Evidence is consistently positive across multiple studies.

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

HbA1c appears to have a consistent beneficial signal in the indexed evidence.

Leading examples

HbA1c · Body weight · Systolic blood pressure

Evidence basis: 7 evidence pairs - 12 studies

Findings Requiring Careful Interpretation

Results that vary across studies or depend on population, study design, duration, or comparator.

Some evidence is positive, but results are not consistent across all studies.

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Body weight is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Leading examples

Body weight · HbA1c · Adverse events incidence

Evidence basis: 7 evidence pairs - 13 studies

Emerging Areas of Research

Early positive signals that require additional high-quality research.

Early findings are encouraging, but stronger trials are needed.

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Systolic blood pressure may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Leading examples

Systolic blood pressure · BMI · Glucose iAUC (OGTT)

Evidence basis: 6 evidence pairs - 10 studies

About this Evidence Brief

This brief summarizes research currently indexed by Dediabetes Evidence Intelligence. It is not a clinical guideline or personalized medical recommendation. Evidence classifications may change as additional studies are indexed.

Suggested citation

—